Major IntReALL related literature 


Progress Report on Paeditric Regulation (EC), 2013

La Leucémie de l´enfant en mots et en images


 Information booklet for patients and parents >> here



How I treat relapsed childhood acute lymphoblastic leukemia. Blood 2012 Oct 4;120(14):2807-16. Epub 2012 Aug 15 doi: 10.1182/blood-2012-02-265884. 

Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approaches. Curr Opin Oncol. 2013 Nov;25(6):707-15. doi: 10.1097/CCO.0000000000000011.

Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. Haematologica January 2015. doi:10.3324/haematol.2014.116707

Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia 2015 Aug;29(8):1648-55. Epub 2015 Mar 9 doi:10.1038/leu.2015.59.

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2016 Dec 20;34(36):4381-4389. Epub 2016 Oct 31.

Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2016 Aug 18;128(7):911-22. doi: 10.1182/blood-2016-03-704973. Epub 2016 May 26

The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood. Br J Haematol. 2017 Feb;176(4):629-636. doi: 10.1111/bjh.14505. Epub 2017 Jan 24

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood. 2017 Mar 16;129(11):e26-e37. doi: 10.1182/blood-2016-09-738070. Epub 2017 Jan 25

Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy. Br J Haematol. 2017 Oct;179(2):272-283. doi: 10.1111/bjh.14877. Epub 2017 Aug 2